Get notified when MCRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Going Concern (unchanged) — Cash runway extended from Q1 2026 to Q3 2026, indicating improved near-term liquidity position following receipt of second installment payment and cost reductions.
Seres extends cash runway to Q3 2026, pauses SER-155 Phase 2, cuts workforce 30%
Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read
Key Changes
-
high
Company paused investment in SER-155 Phase 2 study after completing protocol submission and startup activities, now seeking external funding to advance the program. This follows a 30% workforce reduction in February 2026.
MD&A: SER-155 Phase 2 verify on EDGAR → -
high
Cash runway extended from Q1 2026 to Q3 2026 following receipt of $23.6 million second installment payment in July 2025 and cost reductions. Cash balance stands at $29.8 million as of March 31, 2026, down from $58.8 million year-ago.
MD&A: Liquidity verify on EDGAR → -
high
Strategic pivot announced alongside workforce reduction, paused lead program, and expanded I&I disease focus including SER-603 in IBD and SER-155 in immune checkpoint enterocolitis, suggesting aspirational rather than executed positioning.
MD&A: Strategy verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade MCRB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify